Terms: = Kidney tumors AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
13 results:
1. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
2. Circular RNA DHX33 promotes malignant behavior in ccRCC by targeting miR-489-3p/mek1 axis.
Wang J; Zhang JQ; Zhao XL; Lu JY; Weng ZM; Ding ZM; Yang FQ
Aging (Albany NY); 2020 Jul; 12(14):14885-14896. PubMed ID: 32717723
[TBL] [Abstract] [Full Text] [Related]
3. Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Amoura Z
Blood; 2020 Apr; 135(16):1311-1318. PubMed ID: 32107533
[TBL] [Abstract] [Full Text] [Related]
4. A1CF-promoted colony formation and proliferation of RCC depends on DKK1-MEK/ERK signal axis.
Ni D; Yi Q; Liu J; Hu Y; Lv T; Tan G; Liu Y; Xu L; Xia H; Zhou Q; Xie Y
Gene; 2020 Mar; 730():144299. PubMed ID: 31881249
[TBL] [Abstract] [Full Text] [Related]
5. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.
Ellens H; Johnson M; Lawrence SK; Watson C; Chen L; Richards-Peterson LE
Drug Metab Dispos; 2017 Jun; 45(6):646-656. PubMed ID: 28320730
[TBL] [Abstract] [Full Text] [Related]
6. The selective mek1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract] [Full Text] [Related]
7. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract] [Full Text] [Related]
8. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
Lin L; Zhong K; Sun Z; Wu G; Ding G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):11-22. PubMed ID: 21947243
[TBL] [Abstract] [Full Text] [Related]
9. ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Gard JM; Nagle RB; Dietrich JD; Monks TJ; Lau SS
Toxicol Sci; 2011 Nov; 124(1):75-87. PubMed ID: 21813464
[TBL] [Abstract] [Full Text] [Related]
10. Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
Eulitt PJ; Park MA; Hossein H; Cruikshanks N; Yang C; Dmitriev IP; Yacoub A; Curiel DT; Fisher PB; Dent P
Cancer Biol Ther; 2010 Dec; 10(12):1290-305. PubMed ID: 20948318
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract] [Full Text] [Related]
12. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract] [Full Text] [Related]
13. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P.
Horiguchi A; Oya M; Marumo K; Murai M
Kidney Int; 2002 Mar; 61(3):926-38. PubMed ID: 11849447
[TBL] [Abstract] [Full Text] [Related]
